HIV-1 immunopathogenesis: How good interferon turns bad

被引:151
|
作者
Herbeuval, Jean-Philippe
Shearer, Gene M.
机构
[1] NCI, Expt Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] Univ Paris 05, Hop Necker Enfants Malad, UMR 8147, CNRS, Paris, France
关键词
HIV; interferon; dendritic cells; apoptosis; TRAIL; T cells; lymphoid tissue; DR5; nonprogressor;
D O I
10.1016/j.clim.2006.09.016
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The hallmark of acquired immunodeficiency syndrome (AIDS) is the progressive loss of CD4(+) T cells that results from infection with human immunodeficiency virus type-1 (HIV-1). Despite 25 years of AIDS research, questions remain concerning the mechanisms responsible for HIV-induced CD4(+) T cell depletion. Here we briefly review the in vitro and in vivo literature concerning the protective rote of interferon -alpha (IFN-alpha) in HIV/AIDS. We then develop a laboratory- and clinically supported model of CD4(+) T cell apoptosis in which either infectious or noninfectious HIV-1 induces the production of type I interferon by plasmacytoid dendritic cells (pDC). The interferon produced binds to its receptor on primary CD4(+) T cells resulting in membrane expression of the TNF-retated apoptosis-inducing ligand (TRAIL) death molecule. The binding of infectious or noninfectious HIV-1 to CD4 on these T cells results in expression of the TRAIL death receptor 5 (DR5), leading to the selective death of HIV-exposed CD4(+) T cells. Published by Elsevier Inc.
引用
收藏
页码:121 / 128
页数:8
相关论文
共 50 条
  • [1] How good cholesterol turns bad
    Van Noorden, Richard
    [J]. CHEMISTRY WORLD, 2007, 4 (10): : 13 - 13
  • [2] HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention?
    Haynes, Barton F.
    Nicely, Nathan I.
    Alam, Munir
    [J]. NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2010, 17 (05) : 543 - 545
  • [3] HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention?
    Barton F Haynes
    Nathan I Nicely
    S Munir Alam
    [J]. Nature Structural & Molecular Biology, 2010, 17 : 543 - 545
  • [4] HIV-1 treatment as prevention: the good, the bad, and the challenges
    Smith, Kumi
    Powers, Kimberly A.
    Kashuba, Angela D. M.
    Cohen, Myron S.
    [J]. CURRENT OPINION IN HIV AND AIDS, 2011, 6 (04) : 315 - 325
  • [5] Immunopathogenesis of HIV-1 infection
    Cao, H
    Walker, BD
    [J]. CLINICS IN DERMATOLOGY, 2000, 18 (04) : 401 - 410
  • [6] Regulatory T Cells in HIV-1 Infection: The Good, the Bad, and the Ugly
    Imamichi, Hiromi
    Lane, H. Clifford
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2012, 205 (10): : 1479 - +
  • [7] Opioid-Mediated HIV-1 Immunopathogenesis
    Shilpa Buch
    Palsamy Periyasamy
    Annadurai Thangaraj
    Susmita Sil
    Ernest T. Chivero
    Ashutosh Tripathi
    [J]. Journal of Neuroimmune Pharmacology, 2020, 15 : 628 - 642
  • [8] HIV-1 immunopathogenesis in humanized mouse models
    Zhang, Liguo
    Su, Lishan
    [J]. CELLULAR & MOLECULAR IMMUNOLOGY, 2012, 9 (03) : 237 - 244
  • [9] HIV-1 immunopathogenesis in humanized mouse models
    Liguo Zhang
    Lishan Su
    [J]. Cellular & Molecular Immunology, 2012, 9 : 237 - 244
  • [10] Opioid-Mediated HIV-1 Immunopathogenesis
    Buch, Shilpa
    Periyasamy, Palsamy
    Thangaraj, Annadurai
    Sil, Susmita
    Chivero, Ernest T.
    Tripathi, Ashutosh
    [J]. JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2020, 15 (04) : 628 - 642